Phase IIb AMP Studies: In Vitro Susceptibility of HIV-1 Isolates to Broadly Neutralizing Antibody VRC01 Predicts HIV Prevention Efficacy in MSM, Transgender Persons, and Cisgender Women

January 27-28 and February 3-4, 2021
This pooled analysis of the phase IIb AMP studies observed that in vitro susceptibility of circulating HIV-1 isolates to the broadly neutralizing antibody, VRC01, predicts prevention efficacy in MSM, transgender persons, and cisgender women.
Format: Microsoft PowerPoint (.ppt)
File Size: 292 KB
Released: February 3, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options (CCO) commentary by Dr Zhao Yan on data presented at CROI 2021 on the impact of the COVID-19 pandemic on HIV treatment

Dr. Zhao Yan Released: April 19, 2021

Clinical Care Options (CCO) commentary by Nelly Mugo, MD, on new data from Kenya on STI incidence and on PrEP uptake from CROI 2021

Nelly Mugo, MBChB, MMed, MPH Released: April 15, 2021

Download CCO slides reviewing clinically relevant new data reported at CROI 2021 on a wide range of ART management topics.

Joseph J. Eron, Jr., MD Princy N. Kumar, MD, FIDSA, MACP Daniel R. Kuritzkes, MD Released: April 9, 2021

由专家选择的 2021 年 CROI 中的重要 HIV 数据,包括当前和研究性的 ART 疗法以及孕期和产后的 ART 疗法。数据由 CCO 提供

Princy N. Kumar, MD, FIDSA, MACP Daniel R. Kuritzkes, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: April 9, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue